新股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

製藥與醫學研究概念

NaN

0.000-1.07%

漲家數：- -

跌家數：2

平家數：4

市盈率：- -

高：NaN

開：NaN

低：NaN

收：NaN

成交量：1,021.02萬

成交額：1,070.13萬

市值：68.82億

流通市值：40.18億

資料載入中...

總覽新聞資訊

IX生物製藥擬定向增發募資不低於600萬新元——計劃完成增發

IX生物製藥擬定向增發募資不低於600萬新元已獲Lqn通知函

IX生物製藥擬定向增發募資不低於600萬新元簽署配售協議

美國政府授予IX生物製藥4100萬美元合約資助Wafermine藥物研發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK6506/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK6506","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","market":"SI","secType":"PLATE","nameCN":"製藥與醫學研究概念","latestPrice":3.0169275e-8,"timestamp":1771924326363,"preClose":3.049655e-8,"halted":0,"volume":10210200,"delay":0,"changeRate":-0.010732,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":0,"latestTime":"02-24 17:16:00 SGT","open":3.048026e-8,"high":3.0631075e-8,"low":2.991697e-8,"amount":10701281,"amplitude":0.023416,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771979400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771893000000,1771905600000],[1771909200000,1771924560000]],"pbRate":1.64608,"peRate":10.549281,"turnoverRate":0.00855,"increases":0,"decrements":2,"flats":5,"marketCap":6881536952,"floatMarketCap":4018116275.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","high":3.0631075e-8,"amplitude":0.023416,"preClose":3.049655e-8,"low":2.991697e-8,"pbRate":"1.64608","latestPrice":3.0169275e-8,"volume":10210200,"delay":0,"open":3.048026e-8,"prevYearClose":1.4808467e-7,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0,"secType":"PLATE","market":"SI","turnoverRate":0.00855,"peRate":10.549281,"marketCap":6881536952,"floatMarketCap":4018116275.75,"timestamp":1771924326363,"nameCN":"製藥與醫學研究概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK6506\",,,,undefined,":{"bkCode":"BK6506","up":0,"down":2,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK6506\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1147941925","title":"IX生物製藥擬定向增發募資不低於600萬新元——計劃完成增發","url":"https://stock-news.laohu8.com/highlight/detail?id=1147941925","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147941925?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:29","pubTimestamp":1771925354,"startTime":"0","endTime":"0","summary":"IX生物制药有限公司宣布启动定向增发计划，目标募集资金总额不低于600万新元。此次增发旨在为公司发展注入新动力，目前相关筹备工作已进入最后阶段，预计将按计划顺利完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":0},{"id":"1194800224","title":"IX生物製藥擬定向增發募資不低於600萬新元 已獲Lqn通知函","url":"https://stock-news.laohu8.com/highlight/detail?id=1194800224","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194800224?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 18:47","pubTimestamp":1771498033,"startTime":"0","endTime":"0","summary":"IX生物制药有限公司宣布启动一项定向增发计划，旨在募集总额不低于600万新加坡元的资金。公司已正式收到Lqn通知函，标志着融资进程进入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["42C.SI","BK6506","BK6079"],"gpt_icon":0},{"id":"1109166435","title":"IX生物製藥擬定向增發募資不低於600萬新元 簽署配售協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1109166435","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109166435?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 18:53","pubTimestamp":1770893592,"startTime":"0","endTime":"0","summary":"IX生物制药有限公司宣布启动定向增发计划，拟募集资金总额不低于600万新元。公司已正式签署配售协议，标志着此次融资活动进入实质性推进阶段。本次募资将用于支持公司核心业务发展及管线药物研发，进一步巩固其在生物医药领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0},{"id":"1165474960","title":"美國政府授予IX生物製藥4100萬美元合約 資助Wafermine藥物研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1165474960","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165474960?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 18:46","pubTimestamp":1770893172,"startTime":"0","endTime":"0","summary":"美国政府与IX生物制药签署价值4100万美元的研发合约，专项用于支持其创新药物Wafermine的临床开发。该资金将加速这款针对神经系统疾病的口服速溶薄膜制剂的技术攻关与产业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}